Mrs Stephanie Taylor1, Mrs Emma Woods1
1NSW Helath, Milton Ulladulla, Australia
The ability to communicate is fundamental to quality of life and speech intelligibility is essential to communicative success.
There are more than 6,000,000 patients worldwide who are diagnosed with Parkinson’s Disease (PD) and nearly 90% develop speech signs that may reduce intelligibility.
An intensive behavioural speech treatment targeting voice, Lee Silverman Voice Treatment (LSVT LOUD®), is the gold standard for therapy.
30% of all patients that were referred to outpatient Speech Pathology services in the Shoalhaven Hospital Group (SHG) in 2020 had a diagnosis of Parkinson’s disease.
27% of these patients would have benefited from therapy targeting their speech and voice function.
0% of these patients received evidenced based therapy as our service did not have the means to provide LSVT.
Within 9 months 90% of patients with hypokinetic dysarthria within SHG will have access to evidenced based therapy.
A range of clinical and operational strategies were implemented.
This resulted in the ability to complete LSVT via telehealth.
Our pilot case study involves 3 patients seen via telehealth for the entire LSVT program: 4 sessions per week for 4 weeks.
All patients increased scores with volume, maximum phonation time and intelligibility.
All patients achieved their goals, decreased scores on the Vocal Handicap Index and improved confidence with communication.
Consumer’s opinions of the Speech Pathology service improved and over 14,000 kms of travel was avoided. Staff efficiencies and productivity also increased and the pilot group generated an additional $10, 593 of activity.
Bio to come.